Precigen (PGEN) shares are in focus after the company reported its first full quarter of meaningful PAPZIMEOS product revenue, supported by FDA approval, broad payer coverage, and management’s reiterated path to cash flow breakeven by late 2026.

At a share price of US$4.42, Precigen’s recent earnings update and PAPZIMEOS launch sit against a mixed backdrop, with a 13.33% 1 month share price return and a 10.34% decline over 3 months, yet a very large 1 year total shareholder return suggesting momentum has been rebuilding after earlier weakness.

If PAPZIMEOS has you looking more broadly at healthcare opportunities, this could be a good moment to scan other gene and AI driven therapeutics and check out 32 healthcare AI stocks

With PAPZIMEOS ramping, revenue improving, and the stock still well below analyst targets, the key question now is simple: Is Precigen still undervalued here, or is the market already pricing in future growth?

Most Popular Narrative: 48% Undervalued

With Precigen last closing at $4.42 and the most followed narrative pointing to a fair value of $8.50, the gap between price and expectations is wide enough to warrant a closer look at what is driving that view.

Rapid uptake of PAPZIMEOS in a sizable and previously underserved adult RRP population, combined with strong physician enthusiasm and broad label coverage, supports a multi year ramp in product revenue as pent up demand converts into treated patients.

Curious what sits behind that confidence in PAPZIMEOS ramping over several years, and how revenue, margins, and future earnings are modeled to reach that $8.50 fair value, the full narrative spells out the growth curve, profitability shift, and valuation multiple that have to align for this discount to make sense.

Result: Fair Value of $8.50 (UNDERVALUED)

However, this upbeat story still hinges on PAPZIMEOS continuing to pull through, and any slowdown in uptake or tighter pricing pressure could quickly challenge that 48% discount.

Another View: Rich On Sales

While the narrative and our DCF work suggest Precigen could be undervalued, the current P/S ratio of 49.9x tells a very different story compared with peers at 20.6x and a fair ratio of 3x. That gap points to meaningful valuation risk if sentiment on PAPZIMEOS cools.

Next Steps

The mix of optimism and caution around Precigen will not stay static for long. Use the data, stress test your assumptions, and decide how you feel about its balance of 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better, so use the tools available and keep your watchlist evolving.

• Target shares that look mispriced by using the 50 high quality undervalued stocks to focus on companies with quality fundamentals at lower valuations.
• Strengthen your income stream by checking the 12 dividend fortresses for stocks offering higher yields with an emphasis on resilience.
• Protect your capital by scanning the 66 resilient stocks with low risk scores to find companies with lower risk scores that still meet your return expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.